By Mark Zipkin, Staff Writer
PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led the way with six deals, including three announced on Jan. 29 involving the use of CRISPR technology in a research capacity. Boehringer Ingelheim GmbH announced three academic collaborations and Johnson & Johnson's Janssen Biotech Inc. subsidiary had two.
The way to Janssen is through the gut
Fishburn, C.S. "TBK1 and beyond." BioCentury Innovations (2015)
Martz, L. "CRISPR research for AZ." BioCentury Innovations (2015)